Efficacy of large doses of IL-2-activated human leukocyte antigen haploidentical peripheral blood stem cells on refractory metastatic renal cell carcinoma
Traditional immunotherapy for patients with refractory metastatic renal cell carcinoma (RCC) is limited because the tumors themselves induce immunosuppression. The aim of this article was to evaluate the clinical efficacy of the infusion of a high dose of interleukin (IL)-2-activated allogeneic hapl...
Gespeichert in:
| Veröffentlicht in: | Cancer biotherapy & radiopharmaceuticals 2011-08, Vol.26 (4), p.503-510 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 510 |
|---|---|
| container_issue | 4 |
| container_start_page | 503 |
| container_title | Cancer biotherapy & radiopharmaceuticals |
| container_volume | 26 |
| creator | Cao, Shui Wang, Yun-Liang Ren, Xiu-Bao Yu, Jin-Pu Ren, Bao-Zhu Zhang, Xin-Wei Zhang, Wei-Hong Han, Ying |
| description | Traditional immunotherapy for patients with refractory metastatic renal cell carcinoma (RCC) is limited because the tumors themselves induce immunosuppression. The aim of this article was to evaluate the clinical efficacy of the infusion of a high dose of interleukin (IL)-2-activated allogeneic haploidentical peripheral blood stem cells (haplo-PBSCs) in patients with advanced intractable RCC. Ten advanced RCC patients and their haploidentical relatives, who were haplo-PBSC donors, were enrolled in this study. All patients accepted one cycle of activated haplo-PBSCs. The clinical and immunologic responses were evaluated. A range from 2.3 to 5.5×10(10) of activated haplo-PBSCs were harvested after exposure to recombinant human IL-2 (rhIL-2), along with a significant increase in the proportion of natural killer cells and activated lymphocytes (CD69+ and CD25+). Enhanced cytotoxicity of haplo-PBSCs for RCC was also observed. After treatment, 2 (2/10) cases of partial remission, 6 (6/10) cases of stable disease, and 2 (2/10) cases of progressive disease were identified in these 10 patients. The median progression-free survival of the 10 patients was 5.5 months (3-14 months). The adoptive transfusion of IL-2-activated haplo-PBSCs can induce sustained antitumor effects for advanced intractable RCC patients who have had no response to conventional immunotherapy. |
| doi_str_mv | 10.1089/cbr.2011.0982 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_902362298</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A271665770</galeid><sourcerecordid>A271665770</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-1df2aafbe7e92d1bcc190458249f80d1b31fac381c37faec8a63aaba961a8e613</originalsourceid><addsrcrecordid>eNqFkk1v1DAQhiMEoqVw5IosOHDK1h8bxz5WVYFKK_VCz9bEGe-6JHGwHaT9K_xaHG1BAiFVPnhm9MyrmdFbVW8Z3TCq9KXt4oZTxjZUK_6sOmdN09ZKNfx5iana1rpVzVn1KqUHSqmksn1ZnXGmGJcNP69-3jjnLdgjCY4MEPdI-pAwrentruY12Ox_QMaeHJYRJjLg8i3YY0YCU_Z7nMgB5iH4HktqYSAzRj8fMJawG0LoSco4EovDUEQnEtHFohnikYyYIWUobaU6FX6FiIVo_RRGeF29cDAkfPP4X1T3n26-Xn-pd3efb6-vdrXdMpVr1jsO4DpsUfOeddYyTbeN4lvtFC0FwRxYoZgVrQO0CqQA6EBLBgolExfVx5PuHMP3BVM2o0_rKDBhWJLRlAvJuVZPkkoJwRjnspDv_yEfwhLLjivEldRa0AJ9OEF7GND4yYVcTrNKmiveMimbtl2pzX-o8nocvQ0TOl_qfzXUpwYbQ0rl3maOfoR4NIya1TOmeMasnjGrZwr_7nHWpRux_0P_Non4BXf2vhs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>882869930</pqid></control><display><type>article</type><title>Efficacy of large doses of IL-2-activated human leukocyte antigen haploidentical peripheral blood stem cells on refractory metastatic renal cell carcinoma</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Cao, Shui ; Wang, Yun-Liang ; Ren, Xiu-Bao ; Yu, Jin-Pu ; Ren, Bao-Zhu ; Zhang, Xin-Wei ; Zhang, Wei-Hong ; Han, Ying</creator><creatorcontrib>Cao, Shui ; Wang, Yun-Liang ; Ren, Xiu-Bao ; Yu, Jin-Pu ; Ren, Bao-Zhu ; Zhang, Xin-Wei ; Zhang, Wei-Hong ; Han, Ying</creatorcontrib><description>Traditional immunotherapy for patients with refractory metastatic renal cell carcinoma (RCC) is limited because the tumors themselves induce immunosuppression. The aim of this article was to evaluate the clinical efficacy of the infusion of a high dose of interleukin (IL)-2-activated allogeneic haploidentical peripheral blood stem cells (haplo-PBSCs) in patients with advanced intractable RCC. Ten advanced RCC patients and their haploidentical relatives, who were haplo-PBSC donors, were enrolled in this study. All patients accepted one cycle of activated haplo-PBSCs. The clinical and immunologic responses were evaluated. A range from 2.3 to 5.5×10(10) of activated haplo-PBSCs were harvested after exposure to recombinant human IL-2 (rhIL-2), along with a significant increase in the proportion of natural killer cells and activated lymphocytes (CD69+ and CD25+). Enhanced cytotoxicity of haplo-PBSCs for RCC was also observed. After treatment, 2 (2/10) cases of partial remission, 6 (6/10) cases of stable disease, and 2 (2/10) cases of progressive disease were identified in these 10 patients. The median progression-free survival of the 10 patients was 5.5 months (3-14 months). The adoptive transfusion of IL-2-activated haplo-PBSCs can induce sustained antitumor effects for advanced intractable RCC patients who have had no response to conventional immunotherapy.</description><identifier>ISSN: 1084-9785</identifier><identifier>EISSN: 1557-8852</identifier><identifier>DOI: 10.1089/cbr.2011.0982</identifier><identifier>PMID: 21812652</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Aged ; Aged, 80 and over ; Carcinoma, Renal cell ; Carcinoma, Renal Cell - immunology ; Carcinoma, Renal Cell - pathology ; Carcinoma, Renal Cell - therapy ; Care and treatment ; Cell Differentiation - drug effects ; Cell Differentiation - immunology ; Dosage and administration ; Female ; Haplotypes ; Hematopoietic Stem Cells - drug effects ; Hematopoietic Stem Cells - immunology ; Histocompatibility antigens ; HLA Antigens - immunology ; HLA histocompatibility antigens ; Humans ; Immunotherapy, Adoptive - methods ; Interleukin-2 ; Interleukin-2 - immunology ; Interleukin-2 - therapeutic use ; Kidney Neoplasms - immunology ; Kidney Neoplasms - pathology ; Kidney Neoplasms - therapy ; Male ; Middle Aged ; Neoplasm Metastasis ; Patient outcomes ; Stem cells ; Transplantation ; Treatment Outcome</subject><ispartof>Cancer biotherapy & radiopharmaceuticals, 2011-08, Vol.26 (4), p.503-510</ispartof><rights>COPYRIGHT 2011 Mary Ann Liebert, Inc.</rights><rights>(©) Copyright 2011, Mary Ann Liebert, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-1df2aafbe7e92d1bcc190458249f80d1b31fac381c37faec8a63aaba961a8e613</citedby><cites>FETCH-LOGICAL-c418t-1df2aafbe7e92d1bcc190458249f80d1b31fac381c37faec8a63aaba961a8e613</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21812652$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cao, Shui</creatorcontrib><creatorcontrib>Wang, Yun-Liang</creatorcontrib><creatorcontrib>Ren, Xiu-Bao</creatorcontrib><creatorcontrib>Yu, Jin-Pu</creatorcontrib><creatorcontrib>Ren, Bao-Zhu</creatorcontrib><creatorcontrib>Zhang, Xin-Wei</creatorcontrib><creatorcontrib>Zhang, Wei-Hong</creatorcontrib><creatorcontrib>Han, Ying</creatorcontrib><title>Efficacy of large doses of IL-2-activated human leukocyte antigen haploidentical peripheral blood stem cells on refractory metastatic renal cell carcinoma</title><title>Cancer biotherapy & radiopharmaceuticals</title><addtitle>Cancer Biother Radiopharm</addtitle><description>Traditional immunotherapy for patients with refractory metastatic renal cell carcinoma (RCC) is limited because the tumors themselves induce immunosuppression. The aim of this article was to evaluate the clinical efficacy of the infusion of a high dose of interleukin (IL)-2-activated allogeneic haploidentical peripheral blood stem cells (haplo-PBSCs) in patients with advanced intractable RCC. Ten advanced RCC patients and their haploidentical relatives, who were haplo-PBSC donors, were enrolled in this study. All patients accepted one cycle of activated haplo-PBSCs. The clinical and immunologic responses were evaluated. A range from 2.3 to 5.5×10(10) of activated haplo-PBSCs were harvested after exposure to recombinant human IL-2 (rhIL-2), along with a significant increase in the proportion of natural killer cells and activated lymphocytes (CD69+ and CD25+). Enhanced cytotoxicity of haplo-PBSCs for RCC was also observed. After treatment, 2 (2/10) cases of partial remission, 6 (6/10) cases of stable disease, and 2 (2/10) cases of progressive disease were identified in these 10 patients. The median progression-free survival of the 10 patients was 5.5 months (3-14 months). The adoptive transfusion of IL-2-activated haplo-PBSCs can induce sustained antitumor effects for advanced intractable RCC patients who have had no response to conventional immunotherapy.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Carcinoma, Renal cell</subject><subject>Carcinoma, Renal Cell - immunology</subject><subject>Carcinoma, Renal Cell - pathology</subject><subject>Carcinoma, Renal Cell - therapy</subject><subject>Care and treatment</subject><subject>Cell Differentiation - drug effects</subject><subject>Cell Differentiation - immunology</subject><subject>Dosage and administration</subject><subject>Female</subject><subject>Haplotypes</subject><subject>Hematopoietic Stem Cells - drug effects</subject><subject>Hematopoietic Stem Cells - immunology</subject><subject>Histocompatibility antigens</subject><subject>HLA Antigens - immunology</subject><subject>HLA histocompatibility antigens</subject><subject>Humans</subject><subject>Immunotherapy, Adoptive - methods</subject><subject>Interleukin-2</subject><subject>Interleukin-2 - immunology</subject><subject>Interleukin-2 - therapeutic use</subject><subject>Kidney Neoplasms - immunology</subject><subject>Kidney Neoplasms - pathology</subject><subject>Kidney Neoplasms - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Patient outcomes</subject><subject>Stem cells</subject><subject>Transplantation</subject><subject>Treatment Outcome</subject><issn>1084-9785</issn><issn>1557-8852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkk1v1DAQhiMEoqVw5IosOHDK1h8bxz5WVYFKK_VCz9bEGe-6JHGwHaT9K_xaHG1BAiFVPnhm9MyrmdFbVW8Z3TCq9KXt4oZTxjZUK_6sOmdN09ZKNfx5iana1rpVzVn1KqUHSqmksn1ZnXGmGJcNP69-3jjnLdgjCY4MEPdI-pAwrentruY12Ox_QMaeHJYRJjLg8i3YY0YCU_Z7nMgB5iH4HktqYSAzRj8fMJawG0LoSco4EovDUEQnEtHFohnikYyYIWUobaU6FX6FiIVo_RRGeF29cDAkfPP4X1T3n26-Xn-pd3efb6-vdrXdMpVr1jsO4DpsUfOeddYyTbeN4lvtFC0FwRxYoZgVrQO0CqQA6EBLBgolExfVx5PuHMP3BVM2o0_rKDBhWJLRlAvJuVZPkkoJwRjnspDv_yEfwhLLjivEldRa0AJ9OEF7GND4yYVcTrNKmiveMimbtl2pzX-o8nocvQ0TOl_qfzXUpwYbQ0rl3maOfoR4NIya1TOmeMasnjGrZwr_7nHWpRux_0P_Non4BXf2vhs</recordid><startdate>201108</startdate><enddate>201108</enddate><creator>Cao, Shui</creator><creator>Wang, Yun-Liang</creator><creator>Ren, Xiu-Bao</creator><creator>Yu, Jin-Pu</creator><creator>Ren, Bao-Zhu</creator><creator>Zhang, Xin-Wei</creator><creator>Zhang, Wei-Hong</creator><creator>Han, Ying</creator><general>Mary Ann Liebert, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>201108</creationdate><title>Efficacy of large doses of IL-2-activated human leukocyte antigen haploidentical peripheral blood stem cells on refractory metastatic renal cell carcinoma</title><author>Cao, Shui ; Wang, Yun-Liang ; Ren, Xiu-Bao ; Yu, Jin-Pu ; Ren, Bao-Zhu ; Zhang, Xin-Wei ; Zhang, Wei-Hong ; Han, Ying</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-1df2aafbe7e92d1bcc190458249f80d1b31fac381c37faec8a63aaba961a8e613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Carcinoma, Renal cell</topic><topic>Carcinoma, Renal Cell - immunology</topic><topic>Carcinoma, Renal Cell - pathology</topic><topic>Carcinoma, Renal Cell - therapy</topic><topic>Care and treatment</topic><topic>Cell Differentiation - drug effects</topic><topic>Cell Differentiation - immunology</topic><topic>Dosage and administration</topic><topic>Female</topic><topic>Haplotypes</topic><topic>Hematopoietic Stem Cells - drug effects</topic><topic>Hematopoietic Stem Cells - immunology</topic><topic>Histocompatibility antigens</topic><topic>HLA Antigens - immunology</topic><topic>HLA histocompatibility antigens</topic><topic>Humans</topic><topic>Immunotherapy, Adoptive - methods</topic><topic>Interleukin-2</topic><topic>Interleukin-2 - immunology</topic><topic>Interleukin-2 - therapeutic use</topic><topic>Kidney Neoplasms - immunology</topic><topic>Kidney Neoplasms - pathology</topic><topic>Kidney Neoplasms - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Patient outcomes</topic><topic>Stem cells</topic><topic>Transplantation</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cao, Shui</creatorcontrib><creatorcontrib>Wang, Yun-Liang</creatorcontrib><creatorcontrib>Ren, Xiu-Bao</creatorcontrib><creatorcontrib>Yu, Jin-Pu</creatorcontrib><creatorcontrib>Ren, Bao-Zhu</creatorcontrib><creatorcontrib>Zhang, Xin-Wei</creatorcontrib><creatorcontrib>Zhang, Wei-Hong</creatorcontrib><creatorcontrib>Han, Ying</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Cancer biotherapy & radiopharmaceuticals</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cao, Shui</au><au>Wang, Yun-Liang</au><au>Ren, Xiu-Bao</au><au>Yu, Jin-Pu</au><au>Ren, Bao-Zhu</au><au>Zhang, Xin-Wei</au><au>Zhang, Wei-Hong</au><au>Han, Ying</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of large doses of IL-2-activated human leukocyte antigen haploidentical peripheral blood stem cells on refractory metastatic renal cell carcinoma</atitle><jtitle>Cancer biotherapy & radiopharmaceuticals</jtitle><addtitle>Cancer Biother Radiopharm</addtitle><date>2011-08</date><risdate>2011</risdate><volume>26</volume><issue>4</issue><spage>503</spage><epage>510</epage><pages>503-510</pages><issn>1084-9785</issn><eissn>1557-8852</eissn><abstract>Traditional immunotherapy for patients with refractory metastatic renal cell carcinoma (RCC) is limited because the tumors themselves induce immunosuppression. The aim of this article was to evaluate the clinical efficacy of the infusion of a high dose of interleukin (IL)-2-activated allogeneic haploidentical peripheral blood stem cells (haplo-PBSCs) in patients with advanced intractable RCC. Ten advanced RCC patients and their haploidentical relatives, who were haplo-PBSC donors, were enrolled in this study. All patients accepted one cycle of activated haplo-PBSCs. The clinical and immunologic responses were evaluated. A range from 2.3 to 5.5×10(10) of activated haplo-PBSCs were harvested after exposure to recombinant human IL-2 (rhIL-2), along with a significant increase in the proportion of natural killer cells and activated lymphocytes (CD69+ and CD25+). Enhanced cytotoxicity of haplo-PBSCs for RCC was also observed. After treatment, 2 (2/10) cases of partial remission, 6 (6/10) cases of stable disease, and 2 (2/10) cases of progressive disease were identified in these 10 patients. The median progression-free survival of the 10 patients was 5.5 months (3-14 months). The adoptive transfusion of IL-2-activated haplo-PBSCs can induce sustained antitumor effects for advanced intractable RCC patients who have had no response to conventional immunotherapy.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>21812652</pmid><doi>10.1089/cbr.2011.0982</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1084-9785 |
| ispartof | Cancer biotherapy & radiopharmaceuticals, 2011-08, Vol.26 (4), p.503-510 |
| issn | 1084-9785 1557-8852 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_902362298 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Aged Aged, 80 and over Carcinoma, Renal cell Carcinoma, Renal Cell - immunology Carcinoma, Renal Cell - pathology Carcinoma, Renal Cell - therapy Care and treatment Cell Differentiation - drug effects Cell Differentiation - immunology Dosage and administration Female Haplotypes Hematopoietic Stem Cells - drug effects Hematopoietic Stem Cells - immunology Histocompatibility antigens HLA Antigens - immunology HLA histocompatibility antigens Humans Immunotherapy, Adoptive - methods Interleukin-2 Interleukin-2 - immunology Interleukin-2 - therapeutic use Kidney Neoplasms - immunology Kidney Neoplasms - pathology Kidney Neoplasms - therapy Male Middle Aged Neoplasm Metastasis Patient outcomes Stem cells Transplantation Treatment Outcome |
| title | Efficacy of large doses of IL-2-activated human leukocyte antigen haploidentical peripheral blood stem cells on refractory metastatic renal cell carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T10%3A53%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20large%20doses%20of%20IL-2-activated%20human%20leukocyte%20antigen%20haploidentical%20peripheral%20blood%20stem%20cells%20on%20refractory%20metastatic%20renal%20cell%20carcinoma&rft.jtitle=Cancer%20biotherapy%20&%20radiopharmaceuticals&rft.au=Cao,%20Shui&rft.date=2011-08&rft.volume=26&rft.issue=4&rft.spage=503&rft.epage=510&rft.pages=503-510&rft.issn=1084-9785&rft.eissn=1557-8852&rft_id=info:doi/10.1089/cbr.2011.0982&rft_dat=%3Cgale_proqu%3EA271665770%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=882869930&rft_id=info:pmid/21812652&rft_galeid=A271665770&rfr_iscdi=true |